This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamagishi, S.-i. Articles by Imaizumi, T. Search for Related Content PubMed PubMed Citation Articles by Yamagishi, S.-i. Articles by Imaizumi, T.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:e32.)
© 2007 American Heart Association, Inc.

Letters to the Editor

Serum Levels of Soluble Form of Receptor for Advanced Glycation End Products (sRAGE) May Reflect Tissue RAGE Expression In Diabetes

Sho-ichi Yamagishi; Tsutomu Imaizumi

Department of Medicine, Kurume University School of Medicine, Kurume, Japan

An extract of the first 250 words of the full text is provided, because this article has no abstract.

To the Editor:

I have read two interesting papers about endogenous C-truncated splice isoform of secretory receptor for advanced glycation end products (esRAGE), which were recently published in your journal.^1,2 The findings that esRAGE levels are correlated with serum pentosidine and carboxymethyllysine in type 1 diabetes by Miura et al¹ are consistent with our and Tan’s previous observations that serum levels of total soluble form of RAGE (sRAGE) were positively, but not inversely, correlated with circulating AGE levels in nondiabetic and type 2 diabetic subjects, respectively.^3,4 These observations suggest that endogenous esRAGE or sRAGE levels are not sufficient to eliminate circulating AGEs efficiently in vivo. However, Koyama et al^2,5 recently reported in ATVB that decreased levels of esRAGE were associated with comorbidity including the metabolic syndrome and atherosclerosis and with cardiovascular mortality in end-stage renal disease patients. Therefore, it is unlikely that esRAGE protects against these devastating disorders by working as a decoy receptor for AGEs in vivo. Indeed, they also claimed in their article that pentosidine level was positively, but not inversely, associated with esRAGE.

In contrast to the case of esRAGE, circulating sRAGE levels are increased, rather than decreased, in both type 1 and type 2 diabetic patients.^4,6,7 Further, the following evidence supports the concept that circulating sRAGE may be elevated in response to serum AGE levels and reflect tissue RAGE expression in diabetes, thereby acting as a negative feedback agent against the AGE-elicited vascular injury: (1) RAGE belongs to the same immunoglobulin superfamily as intercellular adhesion molecule-1 . . . [Full Text of this Article]

This article has been cited by other articles:

				R. Pullerits, H. F. d'Elia, A. Tarkowski, and H. Carlsten The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial Rheumatology, July 1, 2009; 48(7): 785 - 790. [Abstract] [Full Text] [PDF]